Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

SEEG-Guided DBS for Schizophrenia

NCT: NCT07671261 · RECRUITING

NCT IDNCT07671261
StatusRECRUITING
Start Date2025-08-17
Completion2028-12-31
SponsorRuijin Hospital (OTHER)
First posted
Last updated

Brief Summary

This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia. Using stereo-electroencephalography (SEEG) to record brain activity, we will identify specific abnormal electrophysiological targets and signal features associated with clinical symptoms, followed by a 12-month open-label stimulation period. The study is conducted in three stages: Stage 1 consists of SEEG brain mapping, screening of intervention targets, and optimization of stimulation parameters; Stage 2 consists of DBS implantation surgery and further optimization of stimulation parameters; Stage 3 is a randomized crossover treatment phase, followed by an open-label treatment period.

Frequently Asked Questions

What is SEEG-Guided DBS for Schizophrenia?

SEEG-Guided DBS for Schizophrenia is a clinical trial registered under NCT07671261. Current status: RECRUITING.

What is the status of NCT07671261?

The current status of NCT07671261 (SEEG-Guided DBS for Schizophrenia) is: RECRUITING.

When did SEEG-Guided DBS for Schizophrenia start?

SEEG-Guided DBS for Schizophrenia started on 2025-08-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.